• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

影响组织型纤溶酶原激活剂与纤溶酶原激活剂抑制剂1相互作用的氨基酸残基。

Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1.

作者信息

Madison E L, Goldsmith E J, Gerard R D, Gething M J, Sambrook J F, Bassel-Duby R S

机构信息

Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas 75235.

出版信息

Proc Natl Acad Sci U S A. 1990 May;87(9):3530-3. doi: 10.1073/pnas.87.9.3530.

DOI:10.1073/pnas.87.9.3530
PMID:2110366
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC53935/
Abstract

Fibrinolysis is regulated in part by the interaction between tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1, a serine protease inhibitor of the serpin family). It is known from our earlier work that deletion of a loop of amino acids (residues 296-302) from the serine protease domain of t-PA suppresses the interaction between the two proteins without altering the reactivity of t-PA towards its substrate, plasminogen. To define more precisely the role of individual residues within this loop, we have used site-directed mutagenesis to replace Lys-296, Arg-298, and Arg-299 with negatively charged glutamic residues. Replacement of all three positively charged amino acids generates a variant of t-PA that associates inefficiently with PAI-1 and is highly resistant to inhibition by the serpin. Two t-PAs with point mutations (Arg-298----Glu and Arg-299----Glu) are partially resistant to inhibition by PAI-1 and associate with the serpin at intermediate rates. Other point mutations (Lys-296----Glu, His-297----Glu, and Pro-301----Gly) do not detectably affect the interaction of t-PA with PAI-1. None of these substitutions has a significant effect on the rate of catalysis by t-PA or on the affinity of the enzyme for its substrate, plasminogen. On the basis of these results, we propose a model in which positively charged residues located in a surface loop near the active site of t-PA form ionic bonds with complementary negatively charged residues C-terminal to the reactive center of PAI-1.

摘要

纤维蛋白溶解部分受组织型纤溶酶原激活剂(t-PA)与纤溶酶原激活剂抑制剂1(PAI-1,丝氨酸蛋白酶抑制剂家族中的一种丝氨酸蛋白酶抑制剂)之间相互作用的调节。我们早期的研究工作表明,从t-PA的丝氨酸蛋白酶结构域中缺失一段氨基酸环(残基296 - 302)可抑制这两种蛋白质之间的相互作用,而不会改变t-PA对其底物纤溶酶原的反应性。为了更精确地确定该环内各个残基的作用,我们使用定点诱变将赖氨酸-296、精氨酸-298和精氨酸-299替换为带负电荷的谷氨酸残基。将所有三个带正电荷的氨基酸替换后产生了一种t-PA变体,它与PAI-1的结合效率低下,并且对丝氨酸蛋白酶抑制剂的抑制具有高度抗性。两个具有点突变(精氨酸-298→谷氨酸和精氨酸-299→谷氨酸)的t-PA对PAI-1的抑制具有部分抗性,并以中等速率与丝氨酸蛋白酶抑制剂结合。其他点突变(赖氨酸-296→谷氨酸、组氨酸-297→谷氨酸和脯氨酸-301→甘氨酸)未检测到对t-PA与PAI-1相互作用的影响。这些取代均未对t-PA的催化速率或该酶对其底物纤溶酶原的亲和力产生显著影响。基于这些结果,我们提出了一个模型,其中位于t-PA活性位点附近表面环中的带正电荷残基与PAI-1反应中心C末端的互补带负电荷残基形成离子键。

相似文献

1
Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1.影响组织型纤溶酶原激活剂与纤溶酶原激活剂抑制剂1相互作用的氨基酸残基。
Proc Natl Acad Sci U S A. 1990 May;87(9):3530-3. doi: 10.1073/pnas.87.9.3530.
2
Serpin-resistant mutants of human tissue-type plasminogen activator.
Nature. 1989 Jun 29;339(6227):721-4. doi: 10.1038/339721a0.
3
Variants of tissue-type plasminogen activator that display extraordinary resistance to inhibition by the serpin plasminogen activator inhibitor type 1.
J Biol Chem. 1997 Jun 6;272(23):14580-5. doi: 10.1074/jbc.272.23.14580.
4
The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.组织型纤溶酶原激活物的可变区-1通过促进催化作用赋予纤溶酶原激活物抑制剂-1对凝血酶的特异性:由异源蛋白质表面环解除动力学阻滞。
J Mol Biol. 1999 Oct 29;293(3):613-27. doi: 10.1006/jmbi.1999.3178.
5
Restoration of serine protease-inhibitor interaction by protein engineering.通过蛋白质工程恢复丝氨酸蛋白酶与抑制剂的相互作用。
J Biol Chem. 1990 Dec 15;265(35):21423-6.
6
Combinatorial mutagenesis of the reactive site region in plasminogen activator inhibitor I.纤溶酶原激活物抑制剂I反应位点区域的组合诱变
J Biol Chem. 1991 May 5;266(13):8495-500.
7
Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator.玻连蛋白调控纤溶酶原激活物抑制剂1与组织型纤溶酶原激活物之间的相互作用。
J Biol Chem. 1991 Jun 5;266(16):10700-7.
8
The plasminogen activator inhibitor-1 binding site in the kringle-2 domain of tissue-type plasminogen activator.组织型纤溶酶原激活物kringle-2结构域中的纤溶酶原激活物抑制剂-1结合位点。
Biochem Biophys Res Commun. 1991 Aug 15;178(3):1160-6. doi: 10.1016/0006-291x(91)91014-4.
9
Selective screening of a large phage display library of plasminogen activator inhibitor 1 mutants to localize interaction sites with either thrombin or the variable region 1 of tissue-type plasminogen activator.对纤溶酶原激活物抑制剂1突变体的大型噬菌体展示文库进行选择性筛选,以定位与凝血酶或组织型纤溶酶原激活物可变区1的相互作用位点。
J Biol Chem. 1996 Mar 29;271(13):7423-8. doi: 10.1074/jbc.271.13.7423.
10
Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells.组织型纤溶酶原激活物 - 1型纤溶酶原激活物抑制剂复合物与HepG2细胞结合所涉及的决定因素的鉴定。
J Biol Chem. 1990 Aug 25;265(24):14093-9.

引用本文的文献

1
Targeting the PAI-1 Mechanism with a Small Peptide Increases the Efficacy of Alteplase in a Rabbit Model of Chronic Empyema.用一种小肽靶向纤溶酶原激活物抑制剂-1机制可提高阿替普酶在兔慢性脓胸模型中的疗效。
Pharmaceutics. 2023 May 14;15(5):1498. doi: 10.3390/pharmaceutics15051498.
2
Precision targeting of the plasminogen activator inhibitor-1 mechanism increases efficacy of fibrinolytic therapy in empyema.纤溶酶原激活物抑制剂-1 机制的精准靶向提高脓胸纤维蛋白溶解治疗的疗效。
Physiol Rep. 2021 May;9(9):e14861. doi: 10.14814/phy2.14861.
3
Structural Biology and Protein Engineering of Thrombolytics.溶栓剂的结构生物学与蛋白质工程
Comput Struct Biotechnol J. 2019 Jul 2;17:917-938. doi: 10.1016/j.csbj.2019.06.023. eCollection 2019.
4
Reactive centre loop dynamics and serpin specificity.反应中心环动力学与丝氨酸蛋白酶抑制剂特异性。
Sci Rep. 2019 Mar 7;9(1):3870. doi: 10.1038/s41598-019-40432-w.
5
Targeting plasminogen activator inhibitor-1 in tetracycline-induced pleural injury in rabbits.靶向纤溶酶原激活物抑制剂-1 治疗四环素诱导的兔胸膜损伤。
Am J Physiol Lung Cell Mol Physiol. 2018 Jan 1;314(1):L54-L68. doi: 10.1152/ajplung.00579.2016. Epub 2017 Aug 31.
6
Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1.纤溶酶原激活物抑制剂-1对组织型纤溶酶原激活物特异性抑制的结构基础
Data Brief. 2016 Jan 6;6:550-5. doi: 10.1016/j.dib.2015.12.050. eCollection 2016 Mar.
7
Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.活性中心环构象和动力学变化揭示了纤溶酶原激活物抑制剂-1(PAI-1)与纤溶酶原激活物及玻连蛋白形成的不同结合复合物。
Protein Sci. 2016 Feb;25(2):499-510. doi: 10.1002/pro.2841. Epub 2015 Dec 2.
8
Crystal Structure of the Michaelis Complex between Tissue-type Plasminogen Activator and Plasminogen Activators Inhibitor-1.组织型纤溶酶原激活剂与纤溶酶原激活剂抑制剂-1米氏复合物的晶体结构
J Biol Chem. 2015 Oct 23;290(43):25795-804. doi: 10.1074/jbc.M115.677567. Epub 2015 Aug 31.
9
Expression of a novel chimeric-truncated tPA in Pichia pastoris with improved biochemical properties.一种具有改善生化特性的新型嵌合截短型组织型纤溶酶原激活剂在毕赤酵母中的表达。
Mol Biotechnol. 2014 Dec;56(12):1143-50. doi: 10.1007/s12033-014-9794-5.
10
Remarkable stabilization of plasminogen activator inhibitor 1 in a "molecular sandwich" complex.纤溶酶原激活物抑制剂 1 在“分子三明治”复合物中得到显著稳定。
Biochemistry. 2013 Jul 9;52(27):4697-709. doi: 10.1021/bi400470s. Epub 2013 Jun 25.

本文引用的文献

1
Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin.人组织型纤溶酶原激活物激活纤溶酶原的动力学。纤维蛋白的作用。
J Biol Chem. 1982 Mar 25;257(6):2912-9.
2
Kinetics of association of serine proteinases with native and oxidized alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin.丝氨酸蛋白酶与天然及氧化型α-1-蛋白酶抑制剂和α-1-抗胰凝乳蛋白酶的结合动力学。
J Biol Chem. 1980 May 10;255(9):3931-4.
3
Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor.血浆中组织型纤溶酶原激活物的失活。与一种新型快速抑制剂形成复合物的证明。
J Biol Chem. 1984 Mar 25;259(6):3644-7.
4
Adaptation of plasminogen activator sequences to known protease structures.纤溶酶原激活剂序列与已知蛋白酶结构的适配。
FEBS Lett. 1983 Jul 4;157(2):219-23. doi: 10.1016/0014-5793(83)80551-1.
5
Cold-sensitive regulatory mutants of simian virus 40.猿猴病毒40的冷敏感调节突变体
J Mol Biol. 1980 Jun 15;140(1):129-42. doi: 10.1016/0022-2836(80)90359-9.
6
Studies on the kinetics of plasminogen activation by tissue plasminogen activator.组织型纤溶酶原激活剂激活纤溶酶原的动力学研究。
Biochim Biophys Acta. 1982 Jun 24;704(3):461-9. doi: 10.1016/0167-4838(82)90068-1.
7
Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single-stranded DNA template.寡核苷酸定向诱变:一种使用两条寡核苷酸引物和单链DNA模板的简单方法。
DNA. 1984 Dec;3(6):479-88. doi: 10.1089/dna.1.1984.3.479.
8
Structure of the complex formed by bovine trypsin and bovine pancreatic trypsin inhibitor. II. Crystallographic refinement at 1.9 A resolution.牛胰蛋白酶与牛胰蛋白酶抑制剂形成的复合物的结构。II. 1.9埃分辨率下的晶体学精修
J Mol Biol. 1974 Oct 15;89(1):73-101. doi: 10.1016/0022-2836(74)90163-6.
9
Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants.内皮细胞产生一种纤溶酶原激活物的潜在抑制剂,该抑制剂可被变性剂激活。
J Biol Chem. 1985 Sep 25;260(21):11581-7.
10
Rapid and efficient site-specific mutagenesis without phenotypic selection.无需表型筛选的快速高效位点特异性诱变。
Proc Natl Acad Sci U S A. 1985 Jan;82(2):488-92. doi: 10.1073/pnas.82.2.488.